Long-term survivors of childhood cancer: The late effects of therapy

Oncologist

Volumn 4, Issue 1, 1999, Pages 45-54

  Schwartz, Cindy L ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Cardiotoxicity; Genitourinary toxicity; Gonadal toxicity; Growth; Late effects; Neurocognitive effects; Pulmonary toxicity; Survivors of childhood cancer

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE;

CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; DEVELOPMENTAL DISORDER; DRUG INDUCED DISEASE; HUMAN; PRIORITY JOURNAL; RADIATION SICKNESS; REVIEW;

EID: 0032997716     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.4-1-45     Document Type: Review

References (67)

1. Meadows AT, Krejmas NL, Belasco JB. The medical cost of cure: sequelae in survivors of childhood cancer. In: Van Eys J, Sullivan MP, eds. Status of the Curability of Childhood Cancers. New York: Raven Press, 1980;263-276.
2. Furst CJ, Lundell M, Ahlback SO et al. Breast hypoplasia following irradiation of the female breast in infancy and early childhood. Acta Oncol 1989;519-523.
3. Rosenfield NS, Haller JQ, Berdon WE. Failure of development of the growing breasts after radiation therapy. Pediatr Radiol 1989;19:124-127.
4. Rostom AY, O'Cathail S. Failure of lactation following radiotherapy for breast cancer (Letter). Lancet 1986:163-164.
5. Kirk JA, Raghupathy P, Stevens MM et al. Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukemia. Lancet 1987;1:190-193.
6. Blatt J, Bercu BB, Gillin JC et al. Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia. J Pediatr 1984;104:182-186.
7. Leiper AD, Stanhope R, Preese MA et al. Precocious or early puberty and growth failure in girls treated for acute lymphoblastic leukemia. Horm Res 1988;30:72-76.
8. Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994;78:1282-1286.
9. Didi M, Didcock E, Davies HA et al. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995;127:63-67.
10. Oberfield SE, Soranno D, Nirenberg A et al. Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediat Adolesc Med 1996;150:589-592.
11. Sklar C, Mertens A, Walter A et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1,800 and 2,400 Centigrays of cranial irradiation. J Pediatr 1993;123:59-64.
12. Silber JH, Littman PS, Meadows AT. Stature loss following skeletal irradiation, for childhood cancer. J Clin Oncol 1990;8:304-312.
13. Glauser TA, Packer RJ. Cognitive deficits in long-term survivors of childhood brain tumors. Childs Nerv Syst 1991;7:2-12.
14. Stehbens JA, Kaleih TA, Noll RB et al. CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsycological and behavioral effects? Neuropsychol Rev 1991;2:147-176.
15. Hoppe-Hirsch E, Renier D, Lellouch-Tubman A et al. Medulloblastoma in childhood-progressive intellectual deterioration. Childs Nerv Syst 1990;6:60-65.
16. Ochs J, Mulher RK, Faircough D et al. Comparison of neuropsychologic function and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial irradiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991;9:145-151.
17. Haupt R, Fears TR, Robison LL et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. JAMA 1994;272:1427-1432.
18. Hays DM, Landsverk J, Sallan SE et al. Educational, occupational, and insurance status of childhood cancer survivors in their fourth and fifth decades of life. J Clin Oncol 1992;10:1397-1406.
19. Ash P. The influence of radiation on fertility in man. Br J Radiol 1990;53:155-158.
20. Kreuser ED, Hetzel WD, Heit W et al. Reproductive and endocrine gonadal functions in adults following multidrug chemotherapy for acute lymphoblastic or undifferentiated leukemia. J Clin Oncol 1988;6:588-595.
21. Koyama H, Wada T, Nishzawa Y et al. Cyclophosphamide induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403-1409.
22. Byrne J, Fears TR, Gail MH et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788-793.
23. Li FP, Gimbreke K, Gelber RD et al. Outcome of pregnancy in survivors of Wilms' tumor. JAMA 1987;257:216-219.
24. Bath LE, Chambers SE, Anderson RA et al. Ovarian and uterine function following treatment for childhood cancer. 5th International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer. Niagara-on-the-Lake, Ontario, Canada. 1998.
25. daCunha MF, Meistrich ML, Fuller LM et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2:571-577.
26. Winkel CA, Fossum GT. Current reproductive technology: consideration for the oncologist. Oncology 1993;7:40-45.
27. Constine LS, Rubin P, Woolf PD et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987;5:1841-1851.
28. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-814.
29. Goorin AM, Borow KM, Goldman A et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer 1981;47:2810-2816.
30. Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672.
31. Lipshultz SE, Colan DE. The use of echocardiography and Holter monitoring in the assessment of anthracycline-treated patients. Proceedings of the Second International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer, Buffalo, NY, 1992.
32. Steinherz LJ, Steinherz PG. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352-361.
33. De Wolf D, Suys B, Maurus R et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996;39:504-512.
34. Bu'Lock FA, Mott MG, Oakhill A et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms and pathophysiology. Br Heart J 1995;73:340-350.
35. Stewart J, Fajardo L. Radiation-induced heart disease: an update. Prog Cardivasc Dis 1984;27:173-194.
36. Boivin JF, Hutchison GB, Lubin JH et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992;69:1241-1247.
37. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-1955.
38. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1199-1203.
39. O'Driscoll BR, Hasleton PS, Taylor PM et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990;323:378-382.
40. Makipernaa A, Heino M, Laitnen L et al. Lung function following treatment of malignant tumors with surgery, radiotherapy, or cyclophosphamide in childhood. Cancer 1989;63:625-630.
41. Samuels ML, Douglas EJ, Holoye PV et al. Large dose bleomycin therapy and pulmonary toxicity. JAMA 1976;235:1117-1120.
42. Van Barneveld PWC, Veenstra G, Sleifer DT et al. Changes in pulmonary function during and after bleomycin treatment in patients with testicular carcinoma. Cancer Chemother Pharmacol 1985;14:168-171.
43. Marina NM, Greenwald CA, Fairclough DL et al. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer 1995;75:1702-1711.
44. Kung FH, Chauvenert AR, Ferree CR et al. Late effects on pulmonary function in children with early stage Hodgkin's disease treated with reduced dose chemoradiotherapy. Proc Am Soc Clin Oncol 1996;15:1332a.
45. Van Leeuwen FE, Klokman WJ, Stovall M et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87:1530-1537.
46. Dewit L, Anninga JK, Hoefnagel CA et al. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990;19:977-983.
47. Goldberg ID, Garnick MB, Bloomer WD. Urinary tract toxic effects of cancer therapy. J Urol 1984;132:1-6.
48. Halperin EC, Constine LS, Tarbell NJ et al. Pediatric Radiation Oncology, New York: Raven Press, 1989.
49. Blachley JD, Hill MB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981;95:628-632.
50. Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology 1991;5:97-112.
51. Skinner R, Pearson AD, Price L et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990;65:732-738.
52. Levine LA, Richie JP. Urological complications of cyclophosphamide. J Urol 1989;141:1063-1069.
53. Sarosy G. Ifosfamide-pharmacologic overview. Semin Oncol 1989;16:2-8.
54. Samra Y, Hertz M, Lindner A. Urinary bladder tumors following cyclophosphamide therapy: a report of two cases with a review of the literature. Med Pediatr Oncol 1985;13:86-91.
55. Dewit L, Ang KK, Vanderschueren E. Acute side effects and late complications after radiotherapy of localized carcinoma of the prostate. Cancer Treat Rep 1983;110:79-89.
56. Hancock S, Cox R, McDougall I. Thyroid disease after treatment of Hodgkin's disease. N Engl J Med 1991;325:599-605.
57. Domann FE, Freitas MA, Gould MN et al. Quantifying the frequency of radiogenic thyroid cancer per clonogenic cell in vivo. Radiat Res 1994;137:330-337.
58. Schmipff SC. Well differentiated thyroid carcinoma: epidemiology, etiology and treatment. Am J Med Sci 1979;278:100-114.
59. Hudson MM, Strickland DK, Jones-Wallace C et al. Chronic hepatitis C (HCV) in childhood cancer survivors. P-16. Conference on Research Issues in Cancer Survivorship, Bethesda, MD. March 1998.
60. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumors among childhood cancer survivors. Br J Cancer 1984;56:339-347.
61. Meadows AT, Baum E, Fossati-Bellani F et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985;3:532-538.
62. Zim S, Collins JM, O'Neill D et al. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983;34:810-817.
63. Ho DJW, Frei E. Clinical pharmacology of 1-β-arabinofuranosyl cytosine. Clin Pharmacol Ther 1971;12:944-954.
64. Hildreth NG, Shore RE, Dvortesky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:1281-1284.
65. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
66. Malkin D, Li FP, Strong LC et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1333-1338.
67. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986;53:661-671.